Company Audentes Therapeutics, Inc.
Equities
US05070R1041
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Andrew Krivoshik
PSD | President | - | - |
Morten Sogaard
COO | Chief Operating Officer | - | 01/22/01 |
Jason Schwartz
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
David Smethurst
LAW | General Counsel | - | 01/21/01 |
Fulvio Mavilio
PRN | Corporate Officer/Principal | - | 18/17/18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kush Parmar
BRD | Director/Board Member | 42 | 01/13/01 |
Alan Beggs
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 45,783,265 | 42,304,829 ( 92.40 %) | 0 | 92.40 % |
Company contact information
Astellas Gene Therapies, Inc.
600 California Street 17th floor
94108, San Francisco
+415 818 1001
http://www.astellasgenetherapies.comSector
1st Jan change | Capi. | |
---|---|---|
+9.58% | 115B | |
+12.41% | 107B | |
-2.59% | 21.6B | |
-12.38% | 22.31B | |
-5.29% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |